VHFIC

The Viral Hemorrhagic Fever Immunotherapeutic Consortium, or VIC, was established in 2014 to develop life-saving antibody therapeutics against some of the world’s deadliest viruses. The VIC represents a field-wide collaboration in which all of the leading laboratories, from over 15 institutions, have united to develop the most efficacious antibody cocktail possible against Ebola virus. This collaborative effort allows each laboratory to contribute their strengths in analytical techniques towards the identification, characterization, and validation of antibodies against the filoviridae family. From isolating novel antibodies against Ebola and testing them in vivo, to the structural analysis of the molecular mechanism for Ebola neutralization, VIC scientists contribute unique insights towards the overall characterization of each antibody. The consortium is funded through a National Institute of Health National Institute of Allergy and Infectious Diseases Centers for Excellence in Translational Research program grant.

Recent News

57e2f600e2606.image

Fort Detrick Researchers Seek Key to Ebola Virus

September 23, 2016

Dr. John Dye, a VIC collaborator, investigates the mechanism behind the ability to survive Ebola virus infection in Uganda.  Travelling to Uganda and collecting samples directly from Ebola survivors allows him to analyze the different physiological mechanisms that have enabled these individuals to survive while many others have perished.  This research contributes to our understanding of … Continued

The VIC has been named as a 2016 Classy Awards Finalist

VIC Selected as Classy Awards Finalist

April 20, 2016

The Viral Hemorrhagic Fever Immunotherapeutic Consortium, or VIC, has been named a Classy Awards Finalist—one of the 100 most innovative nonprofits and social enterprises of 2016! Classy Awards Finalists are a prestigious group of nonprofits and social enterprises selected for their excellence in social innovation and ability to solve a social problem. This year, the … Continued

Featured Video Play Icon

Experimental Immunotherapy Zaps Two Most Lethal Ebola Virus Strains

January 13, 2016

First Step Toward All-Inclusive Treatment – Researchers at Albert Einstein College of Medicine and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) have engineered the first antibodies that can potently neutralize the two deadliest strains of the virus that causes Ebola hemorrhagic fever. The findings, made in mice, are a significant step toward immunotherapies … Continued